Science News
from research organizations

NOS2 isn't good for ER-negative breast cancer patients, study finds

Date:
October 18, 2010
Source:
Journal of Clinical Investigation
Summary:
Breast cancers can be divided into different subtypes. Patients with breast tumors that lack expression of the protein ER (ER-negative breast tumors) have a worse outlook than those with ER-positive breast tumors. Among ER-negative breast tumors, those characterized as basal-like are the most aggressive and difficult to treat. New therapeutic targets for this breast cancer subtype are urgently needed. New research suggests that the protein NOS2 could be a good drug target in this context.
Share:
       
FULL STORY

Breast cancers can be divided into different subtypes based on several criteria, including whether or not they express the protein to which the female hormone estrogen binds; that is, the estrogen receptor (ER). Patients with ER-negative breast tumors have a worse outlook than those with ER-positive breast tumors.

However, even among ER-negative breast tumors, those characterized as basal-like are the most aggressive and difficult to treat. New therapeutic targets for this subtype of breast cancer are urgently needed.

Now, a team of researchers, led by Stefan Ambs, at the National Cancer Institute, Bethesda, report data that suggest that the protein NOS2 could be a good drug target in this context. The data, generated by analysis of human breast cancer samples and cell lines, lead the authors to conclude that high levels of NOS2 are a predictor of survival in patients with ER-negative breast tumors and to suggest that selective NOS2 inhibitors might be of benefit to these individuals.

The research is reported in the Journal of Clinical Investigation.


Story Source:

The above post is reprinted from materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. sharon A. Glynn, Brenda J. Boersma, Tiffany H. Dorsey, Ming Yi, Harris G. Yfantis, Lisa A. Ridnour, Damali N. Martin, Christopher H. Switzer, Robert S. Hudson, David A. Wink, Dong H. Lee, Robert M. Stephens and Stefan Ambs. Increased NOS2 predicts poor survival in estrogen receptor–negative breast cancer patients. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI42059

Cite This Page:

Journal of Clinical Investigation. "NOS2 isn't good for ER-negative breast cancer patients, study finds." ScienceDaily. ScienceDaily, 18 October 2010. <www.sciencedaily.com/releases/2010/10/101018121356.htm>.
Journal of Clinical Investigation. (2010, October 18). NOS2 isn't good for ER-negative breast cancer patients, study finds. ScienceDaily. Retrieved August 27, 2015 from www.sciencedaily.com/releases/2010/10/101018121356.htm
Journal of Clinical Investigation. "NOS2 isn't good for ER-negative breast cancer patients, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/10/101018121356.htm (accessed August 27, 2015).

Share This Page: